Want to see JP:4593 full AI Analyst Report?

Healios KK (4593) Price & Analysis

8 Followers

4593 Stock Chart & Stats

¥370.00

¥3.00(1.60%)

At close: Jan 08 4:00 PM EST

¥370.00

¥3.00(1.60%)

Day’s Range― - ―

52-Week Range¥234.00 - ¥747.00

Previous CloseN/A

Volume811.70K

Average Volume (3M)1.65M

Market Cap

¥34.16B

Enterprise Value¥19.82B

Total Cash (Recent Filing)¥10.87B

Total Debt (Recent Filing)¥2.59B

Price to Earnings (P/E)―

Beta1.15

Next Earnings

Aug 18, 2026

EPS Estimate

-2.43

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-24.18

Shares Outstanding135,002,200

10 Day Avg. Volume1,843,110

30 Day Avg. Volume1,654,023

Financial Highlights & Ratios

PEG Ratio0.23

Price to Book (P/B)6.03

Price to Sales (P/S)283.63

P/FCF Ratio-8.85

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥800.00

Price Target Upside116.22% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-35.24

Revenue Forecast (FY)¥402.20M

Bulls Say, Bears Say

Bulls Say

Improved Balance Sheet ResilienceLower leverage and a materially larger equity base provide a more durable capital cushion versus prior years. This reduces near-term refinancing risk and gives management flexibility to fund clinical programs or negotiate partnerships without immediate debt pressure, supporting multi-quarter R&D continuity.

Specialized Regenerative Medicine FocusA concentrated business model in cell therapy and regenerative medicine creates high technical barriers and differentiated IP opportunities. Structural demand for advanced biologics and licensing/commercialization pathways supports long-term strategic optionality for partnerships, M&A, or premium product pricing.

Improving Free Cash Flow TrendA positive growth rate in free cash flow, even from a negative base, signals improving operational efficiency or timing of cash outflows. If sustained, this trend lowers future external funding needs and increases the company's ability to extend clinical runways or fund key development milestones without immediate dilution.

Bears Say

Heavy Cash BurnSubstantial negative operating and free cash flow indicate the business is consuming cash faster than it generates it, creating persistent funding needs. Over the medium term this increases reliance on dilutive financing, licensing deals, or asset sales, which can impair shareholder value if not addressed.

Deep, Sustained UnprofitabilityVery large net losses and consistently negative operating margins show the company has not yet demonstrated a path to profitability. For a development-stage biotech this magnifies capital risk and means R&D progress must translate into clear clinical or commercial inflection points to justify ongoing investment.

Shrinking Revenue And Negative Gross ProfitDeclining revenue alongside a move to negative gross profit suggests weakening commercial traction and pricing or cost issues at the product/revenue level. Structurally, this undermines internal funding capacity and increases pressure to secure external partnerships or licensing to sustain development programs.

Healios KK News

Healios Files Counterclaim in Payment Dispute with AND Medical

Healios KK ( ($JP:4593) ) has issued an update. Healios K.K. has filed a counterclaim in the Tokyo...

23d ago

4593

Healios Highlights Uncertainty Around FY2026 Q1 Disclosures and Outlook

The latest announcement is out from Healios KK ( ($JP:4593) ). Healios K.K. released materials related to its...

2M ago

4593

Healios Signs ¥144 Million Stem Cell Supernatant Supply Deal With JENECELL

An update from Healios KK ( ($JP:4593) ) is now available. Healios K.K. has agreed to supply human...

3M ago

4593

Healios Wins ¥7 Billion METI Subsidy to Build Regenerative Medicine CDMO Hub in Kobe

Healios KK ( ($JP:4593) ) has provided an update. Healios K.K., a leading Japanese regenerative medicine biotech, is...

3M ago

4593

Healios to Restructure Capital to Eliminate Losses Without Diluting Shareholders

An announcement from Healios KK ( ($JP:4593) ) is now available. Healios K.K. plans to reduce portions of...

4M ago

4593

Healios Proposes New Board Slate Ahead of March Shareholders Meeting

Healios KK ( ($JP:4593) ) just unveiled an update. Healios K.K. has nominated five candidates for its Board...

4M ago

4593

Healios Issues FY2025 Results With Strong Caution on Forward-Looking Data

Healios KK ( ($JP:4593) ) has provided an update. Healios K.K. released its FY2025 financial results materials primarily...

5M ago

4593

Healios Launches Japan Arm of Global Phase 3 Trial for ARDS Stem Cell Therapy

An update from Healios KK ( ($JP:4593) ) is now available. Healios K.K. has begun preparations to initiate...

5M ago

4593

Healios Deepens Alfresa Alliance for Stem Cell Culture Supernatant Distribution in Japan

Healios KK ( ($JP:4593) ) has provided an update. Healios K.K. has signed a letter of intent with...

5M ago

4593

Healios Files Japan Trial Plan for Global Phase 3 ARDS Stem Cell Study

Healios KK ( ($JP:4593) ) has shared an announcement. Healios K.K. has submitted a clinical trial plan notification...

5M ago

4593

4593 FAQ

What was Healios KK’s price range in the past 12 months?

Healios KK lowest stock price was ¥234.00 and its highest was ¥747.00 in the past 12 months.

What is Healios KK’s market cap?

Healios KK’s market cap is ¥34.16B.

When is Healios KK’s upcoming earnings report date?

Healios KK’s upcoming earnings report date is Aug 18, 2026 which is in 47 days.

How were Healios KK’s earnings last quarter?

Healios KK released its earnings results on May 14, 2026. The company reported -¥27.65 earnings per share for the quarter, missing the consensus estimate of -¥11.14 by -¥16.51.

Is Healios KK overvalued?

According to Wall Street analysts Healios KK’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Healios KK pay dividends?

Healios KK does not currently pay dividends.

What is Healios KK’s EPS estimate?

Healios KK’s EPS estimate is -2.43.

How many shares outstanding does Healios KK have?

Healios KK has 135,002,200 shares outstanding.

What happened to Healios KK’s price movement after its last earnings report?

Healios KK reported an EPS of -¥27.65 in its last earnings report, missing expectations of -¥11.14. Following the earnings report the stock price went down -1.163%.

Which hedge fund is a major shareholder of Healios KK?

Currently, no hedge funds are holding shares in JP:4593

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Healios KK

Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.

Healios KK (4593) Earnings & Revenues

Historic Earnings Reports

4593 Stock 12 Month Forecast

Average Price Target

¥800.00

▲(116.22% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"273":"¥273","405":"¥405","537":"¥537","669":"¥669","801":"¥801"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":800,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥800.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":800,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥800.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":800,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥800.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[273,405,537,669,801],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,326,362.46153846153845,398.9230769230769,435.38461538461536,471.8461538461538,508.30769230769226,544.7692307692307,581.2307692307693,617.6923076923076,654.1538461538462,690.6153846153845,727.0769230769231,763.5384615384615,{"y":800,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,326,362.46153846153845,398.9230769230769,435.38461538461536,471.8461538461538,508.30769230769226,544.7692307692307,581.2307692307693,617.6923076923076,654.1538461538462,690.6153846153845,727.0769230769231,763.5384615384615,{"y":800,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,326,362.46153846153845,398.9230769230769,435.38461538461536,471.8461538461538,508.30769230769226,544.7692307692307,581.2307692307693,617.6923076923076,654.1538461538462,690.6153846153845,727.0769230769231,763.5384615384615,{"y":800,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":535,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":432,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":637,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":543,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":499,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":492,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":466,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":274,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":374,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":465,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":407,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":333,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":326,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >